Skip to main content

Table 3 Association between IDOCC participation and quality of care indicators. Results of regression analyses showing the odds ratio of having a manoeuvre performed in patients of IDOCC participants compared to those of non-IDOCC participants for Cancer screening, Access, Chronic disease management and continuity measures

From: High-performing physicians are more likely to participate in a research study: findings from a quality improvement study

 

N

Overall

Model 1 (Unadjusted)

P value

Model 2 (+ Patient)

P value

Model 3 (+ Patient/Physician)

P value

Cancer screening (%)

 Cervical

356820

66

1.28 (1.13–1.45)

<0.001

1.32 (1.08–1.61)

0.01

1.16 (1.01–1.34)

0.04

 Colorectal

213015

41

1.28 (1.11–1.47)

<0.001

1.13 (0.94–1.36)

0.20

1.04 (0.87–1.25)

0.64

 Breast

119162

68

1.34 (1.21–1.49)

<0.001

1.32 (1.19–1.46)

<0.001

1.15 (1.05–1.26)

< 0.01

Access (mean over 2 years)

 All ER visits (/100 indiv)

770491

54.4

0.96 (0.89–1.04)

0.32

0.93 (0.88–0.97)

<0.01

0.93 (0.89–0.98)

< 0.01

 Low urgency ER visits (/100 indiv)

770491

19.8

0.93 (0.82–1.07)

0.31

0.94 (0.87–1.02)

0.15

0.92 (0.84–1.01)

0.07

 Hospitalizations (/1000 indiv)

770491

5.1

0.90 (0.74–1.09)

0.28

0.87 (0.77–0.99)

0.03

0.85 (0.75–0.97)

0.01

Chronic Disease Management (Diabetes, %)

 Eye Exam test

63478

71

1.17 (1.08–1.26)

<0.001

1.15 (1.06–1.25)

<0.01

1.07 (0.98–1.17)

0.11

 HgA1c test

63472

33

1.20 (1.02–1.41)

0.02

1.25 (1.06–1.49)

0.01

1.14 (0.96–1.35)

0.13

 Lipid Tests

63472

58

1.11 (0.94–1.30)

0.21

1.10 (0.93–1.29)

0.27

1.06 (0.90–1.25)

0.46

 ACE inhib or ARB agent

32874

71

1.08 (0.98–1.20)

0.11

1.07 (0.97–1.19)

0.17

1.02 (0.92–1.13)

0.72

 Lipid Lowering agent

32874

66

1.05 (0.94–1.18)

0.37

1.05 (0.93–1.18)

0.46

1.01 (0.90–1.14)

0.82

 Metformin

1815

86

1.24 (0.83–1.86)

0.29

1.16 (0.78–1.72)

0.47

1.16 (0.77–1.76)

0.47

Continuity (%)

 Usual Provider Care Index

808911

69

1.07 (1.04–1.10)

<0.001

1.06 (1.03–1.09)

<0.001

1.06 (1.03–1.09)

< 0.001

 Practice Care Index

808911

77

1.07 (1.04–1.09)

<0.001

1.06 (1.04–1.08)

<0.001

1.04 (1.02–1.06)

< 0.001

  1. Shows the odds ratio (cancer screening, chronic disease management), rate ratio (access measures and comprehensiveness) and risk difference (continuity) and 95% confidence intervals in brackets for IDOCC participants compared to non-IDOCC participants
  2. Statistically significant differences in favour of IDOCC participants are bolded. There were no statistically significant differences in the other direction
  3. ER = Emergency Room
  4. Low urgency ER visits = ER visits triaged to urgency level 4 or 5 (out of a five point scale, with 5 being the least urgent)
  5. Hospitalizations = Admissions for conditions deemed “ambulatory care sensitive”
  6. Emergency room visits are reported per 100 and 1000 individuals, respectively
  7. The continuity “Care Indices” represent the proportion of primary care visits made to the physician to whom they are assigned (Usual Provider) or the practice in which that physician works (Practice)
  8. ACE inhib = Angiotensin Converting Enzyme Inhibitor; ARB = Angiotensin Receptor Blocker
  9. Medications are only evaluated in patients > 65 years and those receiving social assistance
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us